• Einat Engel-Haber, Anat Horev, Priyanka Chablani, Natan M Bornstein, Ashutosh Jadhav, Tudor G Jovin, Vivek Reddy, and Maxim D Hammer.
• Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: einateng@post.tau.ac.il.
• Clin Neurol Neurosurg. 2015 Oct 1; 137: 12-4.

ObjectivesSpontaneous intracerebral hemorrhage (ICH) results in high morbidity and mortality. A target for therapy might be hematoma expansion, which occurs in a significant proportion of patients, and can be exacerbated by antiplatelet medications, such as aspirin. It is not clear whether platelet transfusion neutralizes aspirin. The Aspirin Response Test (ART) is commonly ordered in this patient population, but it is not clear whether the results of this test can help select patients for transfusion of platelets. The aim of our study is to investigate whether a selected group of ICH patients, those with reduced platelet activity ("aspirin responders"), will benefit from platelet transfusion.Materials And MethodsThis retrospective study included 63 patients who were taking aspirin but no other antithrombotic medication prior to the ICH. For each patient, we measured hematoma size by head CT on admission and compared with follow-up head CT 1 day later.ResultsIn the general cohort, 41% of transfused patients and 29% of non-transfused patients had a hematoma expansion. In the "aspirin responders" group, 46% of transfused patients and 22% of non-transfused patients had an expansion.ConclusionsOur data suggest that platelet transfusion following an ICH in "aspirin responders" does not reduce hematoma expansion rates in those patients. A larger prospective study is needed.Copyright © 2015 Elsevier B.V. All rights reserved.

27 keywords...

hide…